Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

@article{Deacon2006DipeptidylPI,
  title={Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.},
  author={Carolyn F Deacon and Jens Juul Holst},
  journal={The international journal of biochemistry & cell biology},
  year={2006},
  volume={38 5-6},
  pages={831-44}
}
Glucagon-like peptide-1 is an insulinotropic hormone with antidiabetic potential due to its spectrum of effects, which include glucose-dependent stimulation of insulin and inhibition of glucagon secretion, tropic effects on the pancreatic beta-cells, inhibition of gastric emptying and the reduction of appetite. Glucagon-like peptide-1 is, however, extremely rapidly inactivated by the serine peptidase, dipeptidyl peptidase IV, so that the native peptide is not useful clinically. A new approach… CONTINUE READING
29 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…